https://psychedelicinvest.com Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry. News, data, company profiles, and market analysis. en-us https://psychedelicinvest.com/algernon-to-acquire-nobrainer-imaging-centers-inc-plans-to-establish-alzheimers-diagnostic-and-treatment-medical-clinics-featuring-new-pet-scan-technology/ https://psychedelicinvest.com/algernon-to-acquire-nobrainer-imaging-centers-inc-plans-to-establish-alzheimers-diagnostic-and-treatment-medical-clinics-featuring-new-pet-scan-technology/ 2025-07-07T20:43:34.000Z VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and… https://psychedelicinvest.com/atai-life-sciences-announces-first-patient-dosed-in-phase-2-study-of-emp-01-for-the-treatment-of-social-anxiety-disorder/ https://psychedelicinvest.com/atai-life-sciences-announces-first-patient-dosed-in-phase-2-study-of-emp-01-for-the-treatment-of-social-anxiety-disorder/ 2025-07-07T20:42:07.000Z NEW YORK and BERLIN, May 13, 2025 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective… https://psychedelicinvest.com/revive-therapeutics-provides-update-on-research-study-evaluating-bucillamine-for-nerve-agent-exposure-4/ https://psychedelicinvest.com/revive-therapeutics-provides-update-on-research-study-evaluating-bucillamine-for-nerve-agent-exposure-4/ 2025-07-07T20:40:29.000Z TORONTO, May 12, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and… https://psychedelicinvest.com/scisparc-clearmind-collaboration-leads-to-publication-of-european-patent-for-psychedelic-based-combination-therapy-for-cocaine-addiction/ https://psychedelicinvest.com/scisparc-clearmind-collaboration-leads-to-publication-of-european-patent-for-psychedelic-based-combination-therapy-for-cocaine-addiction/ 2025-07-07T20:38:24.000Z TEL AVIV, Israel, May 12, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to… https://psychedelicinvest.com/optimi-health-corp-obtains-u-s-fda-drug-establishment-registration/ https://psychedelicinvest.com/optimi-health-corp-obtains-u-s-fda-drug-establishment-registration/ 2025-07-07T20:37:01.000Z Optimi Health Corp. has received its U.S. FDA Establishment Identifier number-a key regulatory step for engaging in FDA filings and compliant supply into the United States. With this designation,… https://psychedelicinvest.com/neural-therapeutics-announces-serfor-permit-renewal-submission-and-extension-of-loi-with-hanf-com/ https://psychedelicinvest.com/neural-therapeutics-announces-serfor-permit-renewal-submission-and-extension-of-loi-with-hanf-com/ 2025-07-07T20:35:23.000Z Toronto, Ontario–(Newsfile Corp. – May 9, 2025) – Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) (“Neural” or the “Company“), an ethnobotanical drug discovery company focused on developing… https://psychedelicinvest.com/filament-health-announces-first-quarter-2025-financial-results-and-operational-highlights/ https://psychedelicinvest.com/filament-health-announces-first-quarter-2025-financial-results-and-operational-highlights/ 2025-07-07T19:26:13.000Z VANCOUVER, BC, May 8, 2025 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (CBOE: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, released… https://psychedelicinvest.com/cybin-announces-additional-u-s-patent-supporting-its-cyb003-breakthrough-therapy-program-in-phase-3-development-for-major-depressive-disorder/ https://psychedelicinvest.com/cybin-announces-additional-u-s-patent-supporting-its-cyb003-breakthrough-therapy-program-in-phase-3-development-for-major-depressive-disorder/ 2025-07-07T19:24:33.000Z Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing… https://psychedelicinvest.com/optimi-health-completes-largest-to-date-mdma-export-to-australia-for-ptsd-therapy/ https://psychedelicinvest.com/optimi-health-completes-largest-to-date-mdma-export-to-australia-for-ptsd-therapy/ 2025-07-07T19:22:51.000Z Vancouver, British Columbia–(Newsfile Corp. – May 8, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a Canadian drug manufacturer and formulator of… https://psychedelicinvest.com/compass-pathways-announces-first-quarter-2025-financial-results-and-business-highlights/ https://psychedelicinvest.com/compass-pathways-announces-first-quarter-2025-financial-results-and-business-highlights/ 2025-06-05T18:13:47.000Z Highlights: 6-week top-line data from Part A of COMP005 phase 3 trial in treatment resistant depression on track for late June Phase 3 COMP006 in TRD on track for 26-week data second half of 2026… https://psychedelicinvest.com/mindbio-issues-restricted-stock-units/ https://psychedelicinvest.com/mindbio-issues-restricted-stock-units/ 2025-06-05T18:11:59.000Z Vancouver, British Columbia –TheNewswire –May 7, 2025– MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a pioneering clinical-stage biopharmaceutical company… https://psychedelicinvest.com/optimi-health-obtains-u-s-fda-drug-establishment-registration/ https://psychedelicinvest.com/optimi-health-obtains-u-s-fda-drug-establishment-registration/ 2025-06-05T18:08:35.000Z Vancouver, British Columbia–(Newsfile Corp. – May 5, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a manufacturer of GMP-certified MDMA and… https://psychedelicinvest.com/mydecine-innovations-group-provides-update-on-annual-financial-statements/ https://psychedelicinvest.com/mydecine-innovations-group-provides-update-on-annual-financial-statements/ 2025-05-28T20:48:40.000Z Vancouver, British Columbia – TheNewswire – May 15, 2025 — Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is providing this update on the status of a management… https://psychedelicinvest.com/psyence-biomed-announces-effective-date-for-1-for-7-97-reverse-stock-split/ https://psychedelicinvest.com/psyence-biomed-announces-effective-date-for-1-for-7-97-reverse-stock-split/ 2025-05-28T20:25:18.000Z New York, New York–(Newsfile Corp. – May 1, 2025) – Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed” or the “Company”) today announced the effective date of its 1-for-7.97 share consolidation… https://psychedelicinvest.com/cybin-to-participate-at-the-28th-annual-milken-institute-global-conference/ https://psychedelicinvest.com/cybin-to-participate-at-the-28th-annual-milken-institute-global-conference/ 2025-05-28T20:23:06.000Z Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and… https://psychedelicinvest.com/silo-pharmas-sp-26-ketamine-implant-meets-all-endpoints-in-fibromyalgia-study/ https://psychedelicinvest.com/silo-pharmas-sp-26-ketamine-implant-meets-all-endpoints-in-fibromyalgia-study/ 2025-04-30T19:12:33.000Z SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug… https://psychedelicinvest.com/pharmala-issues-q2-financial-statements/ https://psychedelicinvest.com/pharmala-issues-q2-financial-statements/ 2025-04-30T19:11:07.000Z TORONTO, April 30, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and… https://psychedelicinvest.com/compass-pathways-establishes-strategic-collaboration-with-healthport-to-inform-the-potential-delivery-of-comp360-synthesized-psilocybin-treatment-in-underserved-communities/ https://psychedelicinvest.com/compass-pathways-establishes-strategic-collaboration-with-healthport-to-inform-the-potential-delivery-of-comp360-synthesized-psilocybin-treatment-in-underserved-communities/ 2025-04-30T19:08:35.000Z Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with… https://psychedelicinvest.com/scisparc-clearmind-collaboration-leads-to-filing-of-international-patent-application-for-novel-treatment-of-anorexia-bulimia-and-other-eating-disorders/ https://psychedelicinvest.com/scisparc-clearmind-collaboration-leads-to-filing-of-international-patent-application-for-novel-treatment-of-anorexia-bulimia-and-other-eating-disorders/ 2025-04-30T19:05:04.000Z TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of… https://psychedelicinvest.com/clearmind-medicine-completes-the-initiation-of-its-alcohol-use-disorder-phase-i-iia-clinical-trial-at-all-current-clinical-sites/ https://psychedelicinvest.com/clearmind-medicine-completes-the-initiation-of-its-alcohol-use-disorder-phase-i-iia-clinical-trial-at-all-current-clinical-sites/ 2025-04-23T17:56:31.000Z Vancouver, Canada, April 23, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and… https://psychedelicinvest.com/cybin-announces-additional-strategic-clinical-site-partnerships-to-support-paradigm-a-multinational-phase-3-program-evaluating-cyb003/ https://psychedelicinvest.com/cybin-announces-additional-strategic-clinical-site-partnerships-to-support-paradigm-a-multinational-phase-3-program-evaluating-cyb003/ 2025-04-23T17:54:47.000Z TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental… https://psychedelicinvest.com/revive-therapeutics-announces-proposed-shares-for-debt-transaction/ https://psychedelicinvest.com/revive-therapeutics-announces-proposed-shares-for-debt-transaction/ 2025-04-23T17:53:00.000Z TORONTO, April 21, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research… https://psychedelicinvest.com/clearmind-medicine-to-host-live-webinar-gazing-through-the-crystal-ball-featuring-leading-psychedelic-experts/ https://psychedelicinvest.com/clearmind-medicine-to-host-live-webinar-gazing-through-the-crystal-ball-featuring-leading-psychedelic-experts/ 2025-04-23T17:49:08.000Z Vancouver, Canada, April 21, 2025 — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel… https://psychedelicinvest.com/awakn-life-sciences-provides-update-on-rd-programs-progressing-novel-therapeutics-for-alcohol-use-disorder-and-ptsd/ https://psychedelicinvest.com/awakn-life-sciences-provides-update-on-rd-programs-progressing-novel-therapeutics-for-alcohol-use-disorder-and-ptsd/ 2025-04-23T17:46:04.000Z Toronto, Ontario–(Newsfile Corp. – January 27, 2025) – Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company focused on… https://psychedelicinvest.com/cybin-partners-with-osmind-to-accelerate-commercial-preparation-for-its-clinical-stage-psychiatry-programs/ https://psychedelicinvest.com/cybin-partners-with-osmind-to-accelerate-commercial-preparation-for-its-clinical-stage-psychiatry-programs/ 2025-04-23T17:28:10.000Z TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental… https://psychedelicinvest.com/psyence-biomed-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency/ https://psychedelicinvest.com/psyence-biomed-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency/ 2025-04-23T17:26:02.000Z New York, New York–(Newsfile Corp. – April 17, 2025) – Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed” or the “Company”) announced today that it received a notification letter dated April 16,… https://psychedelicinvest.com/psyence-group-announces-share-consolidation/ https://psychedelicinvest.com/psyence-group-announces-share-consolidation/ 2025-04-23T17:20:47.000Z TORONTO, April 17, 2025 (GLOBE NEWSWIRE) — Psyence Group Inc. (“Psyence Group” or the “Company”) (CSE: PSYG), announces that the Company will be consolidating all of its issued and outstanding share… https://psychedelicinvest.com/clearmind-medicine-receives-notice-of-allowance-for-united-states-patent-covering-binge-behavior/ https://psychedelicinvest.com/clearmind-medicine-receives-notice-of-allowance-for-united-states-patent-covering-binge-behavior/ 2025-04-23T17:18:59.000Z Vancouver, Canada, April 17, 2025 — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel… https://psychedelicinvest.com/clearmind-medicine-launches-first-u-s-clinical-site-for-its-fda-approved-clinical-trial-to-combat-alcoholism/ https://psychedelicinvest.com/clearmind-medicine-launches-first-u-s-clinical-site-for-its-fda-approved-clinical-trial-to-combat-alcoholism/ 2025-04-23T17:16:47.000Z Vancouver, Canada, April 16, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and… https://psychedelicinvest.com/psyence-biomed-announces-usd500000-follow-on-investment-in-psylabs-and-global-ibogaine-supply-agreement/ https://psychedelicinvest.com/psyence-biomed-announces-usd500000-follow-on-investment-in-psylabs-and-global-ibogaine-supply-agreement/ 2025-04-23T17:15:06.000Z New York, New York–(Newsfile Corp. – April 15, 2025) – Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed” or the “Company”) today announced a strategic follow-on investment of USD $500,000 into… https://psychedelicinvest.com/mindmed-announces-first-patient-dosed-in-phase-3-emerge-study-of-mm120-in-major-depressive-disorder-mdd/ https://psychedelicinvest.com/mindmed-announces-first-patient-dosed-in-phase-3-emerge-study-of-mm120-in-major-depressive-disorder-mdd/ 2025-04-23T17:12:39.000Z NEW YORK–(BUSINESS WIRE)– Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain… https://psychedelicinvest.com/neural-therapeutics-strengthens-ip-portfolio-with-a-patent-application/ https://psychedelicinvest.com/neural-therapeutics-strengthens-ip-portfolio-with-a-patent-application/ 2025-04-23T17:10:26.000Z Toronto, Ontario–(Newsfile Corp. – April 14, 2025) – Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) (“Neural” or the “Company”), an ethnobotanical drug discovery company dedicated to developing… https://psychedelicinvest.com/mindbio-therapeutics-corp-announces-private-placement-and-debt-settlements/ https://psychedelicinvest.com/mindbio-therapeutics-corp-announces-private-placement-and-debt-settlements/ 2025-04-23T17:02:13.000Z Vancouver, British Columbia – TheNewswire – April 11, 2025 – MindBio Therapeutics Corp. (the “Company” or “MindBio”) (Frankfurt: WF6), (CSE:MBIO), a clinical stage biopharma company targeting… https://psychedelicinvest.com/clearmind-medicine-announces-first-u-s-clinical-site-initiation-for-cmnd-100-clinical-trial-in-patients-with-alcohol-use-disorder/ https://psychedelicinvest.com/clearmind-medicine-announces-first-u-s-clinical-site-initiation-for-cmnd-100-clinical-trial-in-patients-with-alcohol-use-disorder/ 2025-04-23T16:59:07.000Z Vancouver, Canada, April 10, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and… https://psychedelicinvest.com/revive-therapeutics-to-investigate-bucillamines-potential-in-cancer-treatment/ https://psychedelicinvest.com/revive-therapeutics-to-investigate-bucillamines-potential-in-cancer-treatment/ 2025-04-23T16:49:05.000Z TORONTO, April 10, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research… https://psychedelicinvest.com/tryptamine-therapeutics-to-launch-groundbreaking-trial-for-binge-eating-disorder-treatment/ https://psychedelicinvest.com/tryptamine-therapeutics-to-launch-groundbreaking-trial-for-binge-eating-disorder-treatment/ 2025-04-23T16:45:14.000Z Tryptamine Therapeutics has signed an agreement with Swinburne University to conduct a world-first clinical trial assessing the safety and efficacy of TRP-8803, an IV-infused psilocin formulation,… https://psychedelicinvest.com/filament-health-announces-fda-authorization-of-phase-2-clinical-trial-studying-pex010-the-companys-botanical-psilocybin-drug-candidate-in-opioid-use-disorder/ https://psychedelicinvest.com/filament-health-announces-fda-authorization-of-phase-2-clinical-trial-studying-pex010-the-companys-botanical-psilocybin-drug-candidate-in-opioid-use-disorder/ 2025-04-23T16:43:15.000Z Vancouver, British Columbia, April 9, 2025 – Filament Health Corp. (OTCQB:FLHLF) (CBOE:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical‐stage natural psychedelic drug development company,… https://psychedelicinvest.com/algernon-pharmaceuticals-receives-notice-of-allowance-from-european-patent-office-for-repirinast-for-kidney-disease/ https://psychedelicinvest.com/algernon-pharmaceuticals-receives-notice-of-allowance-from-european-patent-office-for-repirinast-for-kidney-disease/ 2025-04-15T19:16:45.000Z VANCOUVER, British Columbia, April 08, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage… https://psychedelicinvest.com/clearmind-medicine-announces-the-publication-of-international-patent-application-for-next-gen-psychedelic-compounds-to-treat-mental-health-disorders/ https://psychedelicinvest.com/clearmind-medicine-announces-the-publication-of-international-patent-application-for-next-gen-psychedelic-compounds-to-treat-mental-health-disorders/ 2025-04-15T19:14:49.000Z Vancouver, Canada, April 08, 2025 — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel… https://psychedelicinvest.com/psyence-biomed-signs-loi-with-southern-star-research-to-expand-phase-iib-clinical-trial-in-australia/ https://psychedelicinvest.com/psyence-biomed-signs-loi-with-southern-star-research-to-expand-phase-iib-clinical-trial-in-australia/ 2025-04-15T19:04:34.000Z New York, New York–(Newsfile Corp. – April 8, 2025) – Psyence BioMed (NASDAQ: PBM) (“Psyence BioMed” or the “Company”) today announced the signing of a Letter of Intent (LOI) with Southern Star… https://psychedelicinvest.com/mindbio-issues-warrants-to-haywood-securities/ https://psychedelicinvest.com/mindbio-issues-warrants-to-haywood-securities/ 2025-04-15T18:36:03.000Z Vancouver, British Columbia –TheNewswire -7 April, 2025–MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6),(the “Company” or “MindBio”),is a clinical stage biopharmaceutical company targeting… https://psychedelicinvest.com/mindbio-adopts-new-equity-incentive-plan/ https://psychedelicinvest.com/mindbio-adopts-new-equity-incentive-plan/ 2025-04-03T13:41:02.000Z Vancouver, British Columbia – TheNewswire – April 2, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), a clinical stage biopharmaceutical company pioneering… https://psychedelicinvest.com/revive-therapeutics-announces-acquisition-of-molecular-hydrogen-program/ https://psychedelicinvest.com/revive-therapeutics-announces-acquisition-of-molecular-hydrogen-program/ 2025-04-03T13:37:58.000Z TORONTO, April 01, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research… https://psychedelicinvest.com/clearmind-launches-its-edc-system-to-support-its-phase-i-ii-clinical-trial-of-its-meai-based-treatment/ https://psychedelicinvest.com/clearmind-launches-its-edc-system-to-support-its-phase-i-ii-clinical-trial-of-its-meai-based-treatment/ 2025-04-03T13:35:01.000Z Vancouver, Canada, April 01, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and… https://psychedelicinvest.com/corporate-update-psyence-biomedical-ltd-redefines-psychedelic-medicine-with-a-multi-asset-strategy-advancing-clinical-trials-and-scalable-manufacturing/ https://psychedelicinvest.com/corporate-update-psyence-biomedical-ltd-redefines-psychedelic-medicine-with-a-multi-asset-strategy-advancing-clinical-trials-and-scalable-manufacturing/ 2025-04-03T13:33:30.000Z New York, New York–(Newsfile Corp. – March 31, 2025) – Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed” or the “Company”) releases the following update: Dear Shareholders and Future Investors:… https://psychedelicinvest.com/filament-health-reports-q4-and-year-end-2024-financial-results-and-operational-highlights/ https://psychedelicinvest.com/filament-health-reports-q4-and-year-end-2024-financial-results-and-operational-highlights/ 2025-04-03T13:29:18.000Z VANCOUVER, BC, April 1, 2025 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, released… https://psychedelicinvest.com/neural-therapeutics-commences-trading-on-frankfurt-stock-exchange/ https://psychedelicinvest.com/neural-therapeutics-commences-trading-on-frankfurt-stock-exchange/ 2025-04-03T13:26:02.000Z Toronto, Ontario–(Newsfile Corp. – March 31, 2025) – Neural Therapeutics Inc. (CSE: NURL) (FSE: M6B) (“Neural“or the “Company“), an ethnobotanical drug discovery company dedicated to developing… https://psychedelicinvest.com/mindbio-acquires-life-ai-corp-pty-ltd/ https://psychedelicinvest.com/mindbio-acquires-life-ai-corp-pty-ltd/ 2025-04-03T13:19:57.000Z Vancouver, British Columbia – TheNewswire – March 26, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), a clinical stage biopharmaceutical company… https://psychedelicinvest.com/mydecine-innovations-group-announces-strategic-board-and-management-changes/ https://psychedelicinvest.com/mydecine-innovations-group-announces-strategic-board-and-management-changes/ 2025-04-03T13:18:10.000Z Mydecine Innovations Group has announced significant changes to its board and management team. Peter Field, an experienced entrepreneur with a background in business development and biotech, has… https://psychedelicinvest.com/pharmala-contracts-with-partner-to-act-as-us-distributor/ https://psychedelicinvest.com/pharmala-contracts-with-partner-to-act-as-us-distributor/ 2025-04-03T13:15:13.000Z TORONTO, March 24, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and…